COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Oxaliplatin Plus Capecitabine in Treating Patients With Colorectal, Appendix, or Small Bowel Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00019773
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : April 29, 2015
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase I trial to study the effectiveness of combining oxaliplatin with capecitabine in treating patients who have colorectal, appendix, or small bowel cancer.

Condition or disease Intervention/treatment Phase
Carcinoma of the Appendix Colorectal Cancer Small Intestine Cancer Drug: capecitabine Drug: oxaliplatin Phase 1

Detailed Description:


  • Determine the maximum tolerated dose (MTD) of capecitabine when administered with oxaliplatin in patients with colorectal, appendiceal, or small bowel cancer.
  • Determine the clinical toxic effects associated with this regimen in these patients.
  • Characterize the molecular profile of tumor tissue obtained prior to study entry for determinants of sensitivity to this regimen in this patient population.
  • Characterize the molecular profile of a surrogate normal tissue (bone marrow aspirate) obtained prior to treatment and assess any potential drug-associated induction of DNA damage and inhibition of thymidylate synthase with a repeat bone marrow aspirate during therapy.
  • Assess any clinical activity of this regimen in this patient population.

OUTLINE: This is a dose-escalation study of capecitabine.

Patients receive oxaliplatin IV over 2 hours on day 1 followed by oral capecitabine twice daily on days 1-5 and 8-12. Courses repeat every 3 weeks in the absence of unacceptable toxicity or disease progression.

Cohorts of 3-6 patients receive escalating doses of capecitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Patients are followed every 3 months for 6 months.

PROJECTED ACCRUAL: A total of 106 patients will be accrued for this study within 36 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Official Title: Pilot Study of Oxaliplatin in Combination With Capecitabine in Adult Cancer Patients
Study Start Date : July 1999

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed colorectal, appendiceal, or small bowel cancer
  • Measurable disease
  • No progression after prior capecitabine
  • No brain metastases or leptomeningeal carcinomatosis



  • 18 and over

Performance status:

  • ECOG 0-2

Life expectancy:

  • Not specified


  • WBC at least 3,000/mm^3
  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3


  • Bilirubin normal
  • AST/ALT no greater than 2.5 times upper limit of normal


  • Creatinine normal
  • Creatinine clearance greater than 60 mL/min


  • No symptomatic congestive heart failure
  • No unstable angina pectoris
  • No cardiac arrhythmia


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No sensory neuropathy
  • No history of allergy to platinum compounds
  • No history of allergy to antiemetics appropriate for administration during study
  • No history of intolerance to fluorouracil
  • No uncontrolled concurrent illness that would preclude study entry
  • No ongoing or active infection requiring IV antibiotics
  • HIV negative


Biologic therapy:

  • At least 4 weeks since prior immunotherapy and recovered


  • See Disease Characteristics
  • Recovered from prior chemotherapy
  • No more than 2 prior systemic chemotherapy regimens for metastatic disease
  • At least 6 weeks since prior nitrosoureas or mitomycin
  • At least 8 weeks since prior eniluracil
  • At least 3 months since prior suramin
  • At least 4 weeks since other prior chemotherapy

Endocrine therapy:

  • Not specified


  • Recovered from prior radiotherapy
  • At least 2 weeks since prior radiotherapy to no more than 20% of bone marrow reserve
  • At least 4 weeks since prior radiotherapy to at least 21% of bone marrow reserve


  • Recovered from prior surgery


  • At least 4 weeks since prior sorivudine or brivudine and recovered
  • No concurrent sorivudine or brivudine
  • No other concurrent investigational agents
  • No other concurrent anticancer therapy or commercial agents

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00019773

Layout table for location information
United States, Maryland
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
Bethesda, Maryland, United States, 20892-1182
Sponsors and Collaborators
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: Eva Szabo, MD National Cancer Institute (NCI)
Publications of Results:
Leonard G, Wright M, Quinn M, et al.: Survey of oxaliplatin-associated neurotoxicity with an interview-based questionnaire. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-3018, 2003.
Thomas R, Quinn M, Wilson R, et al.: A phase I trial of capecitabine (CAPE) & oxaliplatin (OHP). [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-530, 2001.

Layout table for additonal information Identifier: NCT00019773    
Obsolete Identifiers: NCT00001817
Other Study ID Numbers: CDR0000067201
First Posted: January 27, 2003    Key Record Dates
Last Update Posted: April 29, 2015
Last Verified: April 2003
Keywords provided by National Cancer Institute (NCI):
stage I colon cancer
stage II colon cancer
stage III colon cancer
stage IV colon cancer
stage 0 colon cancer
stage 0 rectal cancer
stage I rectal cancer
stage II rectal cancer
stage III rectal cancer
stage IV rectal cancer
recurrent colon cancer
recurrent rectal cancer
small intestine adenocarcinoma
small intestine lymphoma
small intestine leiomyosarcoma
recurrent small intestine cancer
carcinoma of the appendix
Additional relevant MeSH terms:
Layout table for MeSH terms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Intestinal Diseases
Digestive System Diseases
Gastrointestinal Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents